基于VOSviewer软件对肾癌靶向治疗研究热点和趋势的可视化分析

Visual analysis of research hotspots and trends in renal cell carcinoma targeted therapy based on VOSviewer software

  • 摘要:
    目的 基于VOSviewer软件可视化分析肾癌靶向治疗的研究现状、热点和前沿。
    方法 从Web of Science(WOS)核心合集数据库中检索2006年1月1日—2023年12月31日发表的有关肾癌靶向治疗的文献, 筛选出符合标准的文献,通过VOSviewer软件对文献进行计量分析和可视化分析。
    结果 筛选后共获得1 009篇文献,年发文量总体呈上升趋势; 发文量排名前3位的国家依次是美国、中国和意大利,发文量排名前3位的机构依次是哈佛大学、得克萨斯大学和法国综合癌症中心。核心作者合作网络分析结果显示,美国和英国的研究人员在该领域的合作较为紧密,而中国与国外的合作较少,合作网络比较松散。选取高频作者关键词进行共现聚类分析,共生成9个聚类,热点主要集中于靶向与免疫联合治疗、疗效、预后、耐药性、靶点及生物标志物等方面。
    结论 近十几年来,肾癌的靶向治疗研究取得显著进展,然而,靶向药物的耐药性和不良反应仍然是临床治疗中的难点。针对靶向药物耐药机制、新型靶向药物及有效预测生物标志物的相关研究显著增加。掌握该领域的发展趋势至关重要, VOSviewer可视化分析可展现该领域的现状、热点及前沿,为研究者提供直观的参考依据。

     

    Abstract:
    Objective To conduct a visual analysis of the current status, hotspots, and frontiers of research on renal cell carcinoma targeted therapy using VOSviewer software.
    Methods Literature related to renal cell carcinoma targeted therapy published between January 1, 2006 and December 31, 2023, from the Web of Science (WOS) Core Collection database were retrieved. Eligible articles were screened and subjected to bibliometric and visual analysis using VOSviewer software.
    Results A total of 1, 009 articles were selected, with an overall increasing trend in annual publication volume. The top three countries in terms of publication output were the United States, China, and Italy, while the top three institutions were Harvard University, The University of Texas, and France Uni-cancer Institute. The analysis of the core author collaboration network revealed close collaboration among researchers in the United States and the United Kingdom, whereas collaboration between China and foreign countries was limited, resulting in a relatively loose collaboration network. Through co-occurrence clustering analysis of high-frequency author keywords, nine clusters were generated, with hotspots focusing on targeted and immune combination therapy, efficacy, prognosis, drug resistance, targets, and biomarkers.
    Conclusion Remarkable progress has been made in renal cell carcinoma targeted therapy research over the past decade; however, drug resistance and adverse reactions to targeted therapies remain challenges in clinical treatment. Research related to targeted drug resistance mechanisms, novel targeted drugs, and effective predictive biomarkers has significantly increased. Grasping the developmental trends in this fieldis crucial, and VOSviewer's visual analysis can offer an intuitive representation of the current status, hotspots, and frontiers, thereby providing researchers with a valuable reference.

     

/

返回文章
返回